Sugi Predict

Sugi Predict / Compounds / Oxytocin

Oxytocin

Oxytocin

SCHEMBL7658368

CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O.NCC(=O)O

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OXTR

The experimentally established mechanism targets of Oxytocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ OXTR known ✓ P30559 12/20 0.95
▸ AVPR1A P37288 7/20 0.95
▸ AVPR2 P30518 6/20 0.95
▸ AVPR1B P47901 6/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxytocin SCHEMBL20707334 0.97 OXTR (1.00) OXTRAVPR1AAVPR2AVPR1B
Oxytocin SCHEMBL14085374 0.97 OXTR (1.00) OXTRAVPR1AAVPR2AVPR1B
Oxytocin SCHEMBL21527573 0.97 OXTR (1.00) OXTRAVPR1AAVPR2AVPR1B
Oxytocin SCHEMBL16373316 0.97 OXTR (1.00) OXTRAVPR1AAVPR2AVPR1B
Oxytocin SCHEMBL1173243 0.97 OXTR (1.00) OXTRAVPR1AAVPR2AVPR1B
Oxytocin SCHEMBL8370159 0.97 OXTR (1.00) OXTRAVPR1AAVPR2AVPR1B
Oxytocin SCHEMBL29048 0.97 OXTR (1.00) OXTRAVPR1AAVPR2AVPR1B
Oxytocin SCHEMBL2126148 0.97 OXTR (0.97) OXTRAVPR1AAVPR2AVPR1B
Oxytocin SCHEMBL1661474 0.96 OXTR (0.96) OXTRAVPR1AAVPR2AVPR1B
SCHEMBL15511486 0.96 OXTR (0.94) OXTRAVPR1AAVPR2AVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1194570-A1 FUSION PROTEINS INCORPORATING LYSOZYME PPL Therapeutics (Scotland) Limited (GB) 2002-04-10 — — EP disclosed
WO-2001000855-A1 FUSION PROTEINS INCORPORATING LYSOZYME PPL THERAPEUTICS (SCOTLAND) LTD. (GB) 2001-01-04 — — WO disclosed
EP-0696318-A4 CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES IGEN INC (US) 1998-04-15 — — EP disclosed
EP-0753059-A1 PEPTIDE PRODUCTION AS FUSION PROTEIN IN TRANSGENIC MAMMAL MILK PPL Therapeutics (Scotland) Limited (GB) 1997-01-15 — — EP disclosed
EP-0696318-A1 CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES IGEN, INC. (a California corporation) (US) 1996-02-14 — — EP disclosed
WO-1995027782-A1 PEPTIDE PRODUCTION AS FUSION PROTEIN IN TRANSGENIC MAMMAL MILK PPL THERAPEUTICS (SCOTLAND) LTD (GB) 1995-10-19 — — WO disclosed
WO-1994025573-A1 CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES IGEN, INC. (US) 1994-11-10 — — WO disclosed
Send feedback